鴻富瀚(301086.SZ):開封瀚卓擬減持不超過2%股份
格隆匯2月19日丨鴻富瀚(301086.SZ)公佈,股東開封市瀚卓創業投資合夥企業(有限合夥)(簡稱“開封瀚卓”)計劃在2025年3月13日至2025年6月12日期間以集中競價及大宗交易方式減持本公司股份1,800,000股(佔本公司總股本比例2.00%)。其中,以集中競價交易方式減持的,在任意連續90個自然日內減持股份的總數不超過900,000股,即不超過公司總股本的1.00%;以大宗交易方式減持的,在任意連續90個自然日內減持股份的總數不超過900,000股,即不超過公司總股本的1.00%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.